RUNX3 and lymphoma: C-MYC inhibitors are of particular interest in multiple aggressive lymphomas, and treatment of ENKTL cell lines with a small-molecule novel MYC inhibitor caused downregulation of both MYC and RUNX3 and, subsequently, apoptosis [67].